BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $105 | $111 | $305 | $504 |
| Short-Term Investments | $216 | $278 | $120 | $3 |
| Receivables | $79 | $57 | $51 | $29 |
| Inventory | $8 | $29 | $28 | $16 |
| Other Curr. Assets | $14 | $21 | $14 | $13 |
| Total Curr. Assets | $422 | $496 | $517 | $566 |
| Property Plant & Equip (Net) | $20 | $21 | $9 | $15 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $22 | $0 | $18 | $7 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $27 | $0 | $7 | $0 |
| Total NC Assets | $68 | $21 | $34 | $22 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $490 | $517 | $550 | $588 |
| Liabilities | – | – | – | – |
| Payables | $12 | $21 | $14 | $28 |
| Short-Term Debt | $35 | $3 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $3 |
| Deferred Revenue | $0 | $0 | $1 | $1 |
| Other Curr. Liab. | $113 | $126 | $87 | $70 |
| Total Curr. Liab. | $160 | $150 | $106 | $104 |
| LT Debt | $806 | $823 | $739 | $591 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $806 | $823 | $739 | $591 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $10 | $14 | $8 | $8 |
| Total Liabilities | $966 | $972 | $845 | $695 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2 | $2 | $2 | $2 |
| Retained Earnings | -$1,770 | -$1,681 | -$1,455 | -$1,208 |
| AOCI | $1 | $1 | $0 | $0 |
| Other Equity | $1,291 | $1,222 | $1,158 | $1,098 |
| Total Equity | -$476 | -$456 | -$295 | -$107 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $490 | $517 | $550 | $588 |
| Net Debt | $736 | $715 | $437 | $89 |